Abstract
AB062. LAG3 gene as a potential prognostic factor and tumor microenvironment remodeling indicator in thymic epithelial tumors: a TCGA data-based study
Mediastinum
2024;
8:
AB062
(30 December 2024)
Abstract
AB061. Long-term outcomes and characteristics of unresectable or inoperable thymic malignancies
Mediastinum
2024;
8:
AB061
(30 December 2024)
Abstract
AB060. Multiplex immunofluorescence analysis of potential targets in thymic epithelial tumors
Mediastinum
2024;
8:
AB060
(30 December 2024)
Abstract
AB059. The antero-superior mediastinum as unique metastatic site of primary unknown desmoplastic melanoma: a case report
Mediastinum
2024;
8:
AB059
(30 December 2024)
Abstract
AB058. Rebound thymic hyperplasia and immune related adverse events: reality or fantasy—a case report
Mediastinum
2024;
8:
AB058
(30 December 2024)
Abstract
AB057. The practice, intent, and outcome of radiotherapy in thymic epithelial tumors—results from a national cohort
Mediastinum
2024;
8:
AB057
(30 December 2024)
Abstract
AB056. Spatial analysis of T-cell development in type B2 thymoma tumour microenvironment at single-cell resolution
Mediastinum
2024;
8:
AB056
(30 December 2024)
Abstract
AB055. Tumor-T cell interactions in thymic epithelial tumors
Mediastinum
2024;
8:
AB055
(30 December 2024)
Abstract
AB054. A case report of thymoma resection with invasion into the superior vena cava
Mediastinum
2024;
8:
AB054
(30 December 2024)
Abstract
AB053. Assessing the predictive significance of tumor size in thymoma and thymic carcinoma: an analysis utilizing SEER database with propensity matching
Mediastinum
2024;
8:
AB053
(30 December 2024)
Abstract
AB052. Rare tumors biobanking and artificial intelligence (AI): complexity and synergism
Mediastinum
2024;
8:
AB052
(30 December 2024)
Abstract
AB051. Phase II, neo-adjuvant pembrolizumab, paclitaxel, carboplatin therapy followed by post operational pembrolizumab consolidation in locally advanced thymic epithelial tumor
Mediastinum
2024;
8:
AB051
(30 December 2024)
Abstract
AB050. SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma
Mediastinum
2024;
8:
AB050
(30 December 2024)
Abstract
AB049. Sequential induction chemoradiotherapy for locally advanced thymic tumors: a phase II clinical trial
Mediastinum
2024;
8:
AB049
(30 December 2024)
Abstract
AB048. The feasibility and efficacy of induction therapy followed by surgery for advanced thymic carcinoma
Mediastinum
2024;
8:
AB048
(30 December 2024)
Abstract
AB047. Comparison of outcomes of minimally invasive surgery versus sternotomy for early-stage thymic epithelial tumors: a single-center retrospective analysis
Mediastinum
2024;
8:
AB047
(30 December 2024)
Abstract
AB046. Clinical landscape and immunological features of patients with thymic carcinoma
Mediastinum
2024;
8:
AB046
(30 December 2024)
Abstract
AB045. Impact of relative dose intensity of platinum-base chemotherapy as first-line treatment in patients with thymic epithelial tumors
Mediastinum
2024;
8:
AB045
(30 December 2024)
Abstract
AB044. Surveillance trends after resection for thymic malignancy
Mediastinum
2024;
8:
AB044
(30 December 2024)
Abstract
AB043. One case report of recurrence of atypical A thymoma subsequent to undergoing surgery for type AB thymoma
Mediastinum
2024;
8:
AB043
(30 December 2024)
Abstract
AB042. Deep dive into the NEJM study suggesting health consequences after thymectomy
Mediastinum
2024;
8:
AB042
(30 December 2024)
Abstract
AB041. Deep learning discriminates thymic epithelial tumors histological subtypes using digital pathology
Mediastinum
2024;
8:
AB041
(30 December 2024)
Abstract
AB040. Thymic epithelial tumors and haematological malignancies: a monocentric experience
Mediastinum
2024;
8:
AB040
(30 December 2024)
Abstract
AB039. Complex management of thymic epithelial tumors associated with immuno- haematological disorders at the diagnosis: case reports of our experience
Mediastinum
2024;
8:
AB039
(30 December 2024)
Abstract
AB038. Thymomatous myasthenia gravis is associated with fluctuations in CD4-positive T-cell subsets through the activity of the PI3K-Akt-mTOR pathway
Mediastinum
2024;
8:
AB038
(30 December 2024)
Abstract
AB037. AI-powered differentiation of thymomas (A and B3) and thymic carcinoma using histopathological analysis of H&E whole slide images
Mediastinum
2024;
8:
AB037
(30 December 2024)
Abstract
AB036. The contribution of H.K. Müller-Hermelink to the understanding of human thymic pathology
Mediastinum
2024;
8:
AB036
(30 December 2024)
Abstract
AB035. Mediastinal lesion characterization and prognostication using diffusion MRI: from whole lesion to target zone with dynamic approach
Mediastinum
2024;
8:
AB035
(30 December 2024)
Abstract
AB034. Single-cell RNA-seq reveals altered gene expression and cellular composition in thymic epithelial cells of type B thymoma
Mediastinum
2024;
8:
AB034
(30 December 2024)
Abstract
AB033. Impact of tumor-infiltrating lymphocytes, tertiary lymphoid structures, and blood inflammatory markers in thymic cancer patients undergoing surgery
Mediastinum
2024;
8:
AB033
(30 December 2024)
Abstract
AB032. Clinical outcome and immunophenotype in patients with thymic epithelial tumors
Mediastinum
2024;
8:
AB032
(30 December 2024)
Abstract
AB031. Clinical outcome and serum cytokinome profile in patients with thymic epithelial tumors
Mediastinum
2024;
8:
AB031
(30 December 2024)
Abstract
AB030. Metabolic profiles and clinical outcome in patients with thymic epithelial tumors
Mediastinum
2024;
8:
AB030
(30 December 2024)
Abstract
AB029. Short-term outcomes of uniportal subxiphoid thoracoscopic thymectomy for anterior mediastinal tumors
Mediastinum
2024;
8:
AB029
(30 December 2024)
Abstract
AB028. Spatial transcriptomics to dissect the cellular heterogeneity in thymic carcinoma
Mediastinum
2024;
8:
AB028
(30 December 2024)
Abstract
AB027. Insights into hemi-clamshell incision for mediastinal tumor resection
Mediastinum
2024;
8:
AB027
(30 December 2024)
Abstract
AB026. Paraplegia as a first clinical presentation of giant cell tumor of the thoracic spine presenting as a posterior mediastinal tumor with cutaneous tuberculosis: a case report
Mediastinum
2024;
8:
AB026
(30 December 2024)
Abstract
AB025. Primary posterior mediastinal benign leiomyoma arising from accessory hemiazygos vein: a case report
Mediastinum
2024;
8:
AB025
(30 December 2024)
Abstract
AB024. Evaluation of surgical treatment of myasthenia gravis complicated thymoma
Mediastinum
2024;
8:
AB024
(30 December 2024)
Abstract
AB023. The new TNM classification and Masaoka staging system prognosis of thymoma: a retrospective single-center study
Mediastinum
2024;
8:
AB023
(30 December 2024)